New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 12, 2014
08:39 EDTCMRXChimerix shares remain undervalued, says Cowen
Cowen believes shares of Chimerix remain undervalued following its dinner management. The firm remains confident its SUPPRESS trial for brincidofovir will succeed in 2015 and expects other opportunities for the drug to materialize in 2014. Shares are Outperform rated with a $27 price target.
News For CMRX From The Last 14 Days
Check below for free stories on CMRX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 2, 2014
08:22 EDTCMRXChimerix awarded $17M in contract extension from BARDA
Chimerix announced an award of $17.0M through the extension of its contract with the Biomedical Advanced Research and Development Authority, or BARDA, for the development of its broad spectrum antiviral brincidofovir as a medical countermeasure to treat smallpox. Chimerix received the initial award in February 2011 which supported early research and development of brincidofovir in animal models of smallpox. This contract extension provides an additional $17.0M to Chimerix for a period of 15 months, and will support Phase 3 trials expected to initiate in the second half of 2014. This contract extension with BARDA supports research and development of brincidofovir as a treatment for smallpox infections, but does not include a purchase option for the Strategic National Stockpile.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use